Advertisement
The presentation will be webcast and accessible at the Investor Relationssection of the Company's website at:http://www.genta.com/investorrelation/events.html.
Advertisement
The presentation will be archived for 30 days.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversifiedproduct portfolio that is focused on delivering innovative products for thetreatment of patients with cancer. The Company's research platform isanchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense(R) (oblimersen sodium)Injection is the Company's lead compound from its oligonucleotide program.The leading drug in Genta's small molecule program is Ganite(R) (galliumnitrate injection), which the Company is exclusively marketing in the U.S. fortreatment of symptomatic patients with cancer related hypercalcemia that isresistant to hydration. Genta is partnered with IDIS (www.idispharma.com) ona program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more informationabout Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect tobusiness conducted by Genta Incorporated. By their nature, forward-lookingstatements and forecasts involve risks and uncertainties because they relateto events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:
The Company does not undertake to update any forward-looking statements.There are a number of factors that could cause actual results and developmentsto differ materially. For a discussion of those risks and uncertainties,please see the Company's Annual Report on Form 10-K for 2006 and its mostrecent quarterly report on Form 10-Q.-- the Company's ability to obtain necessary regulatory approval for Genasense(R) from the U.S. Food and Drug Administration ("FDA") or European Medicines Agency ("EMEA"); -- the safety and efficacy of the Company's products or product candidates; -- the Company's assessment of its clinical trials; -- the commencement and completion of clinical trials; -- the Company's ability to develop, manufacture, license and sell its products or product candidates; -- the Company's ability to enter into and successfully execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the Company's ability to obtain sufficient financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of litigation that has been brought against the Company and its officers and directors and any proposed settlement of such litigation; and -- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
SOURCE Genta Incorporated
